Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Selecta Biosciences
Biotech
Astellas puts the cork back in $350M Xork deal with Cartesian
Astellas paid $10 million upfront and offered $340 million in biobucks to license Xork from Selecta.
Max Bayer
Mar 14, 2024 10:41am
Selecta fuses with Cartesian in reverse merger
Nov 13, 2023 10:30am
Selecta narrows focus to gout drug, freezing rest of pipeline
Aug 17, 2023 8:18am
Selecta lays off 25% as unpartnered gene therapies dropped
May 5, 2023 10:45am
Selecta, Sobi rout gout in phase 3 trials to take on Horizon
Mar 21, 2023 7:40am
Astellas' intergalactic quest finds 2 pacts with Twist, Selecta
Jan 9, 2023 10:27am
